Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702· Phase 2· AstraZeneca· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)
NCT06549426· Phase 3· University of Twente· Source
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640· Phase 1· Bayer· Source
Recruiting
Hypertonic Lactate After Cardiac Arrest
NCT05004610· Phase 2· Erasme University Hospital· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· Phase 2· Loxo Oncology, Inc.· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· Phase 3· AstraZeneca· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· Phase 3· AstraZeneca· Source
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955· Phase 2· BioAegis Therapeutics Inc.· Source
Recruiting
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Active, not recruiting
A study to test trimodulin in adult hospitalized patients with severe pneumonia
2022-501352-28-00· Phase 3· Biotest GmbH & Co. KGaA· Source
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· Phase 3· UNICANCER· Source
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
2023-506986-74-00· Phase 1/2· F. Hoffmann-La Roche AG· Source
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
2024-511850-34-00· Phase 1/2· Institut Jules Bordet· Source
Active, not recruiting
ASPIRIN Trial Belgium
NCT03464305· Phase 3· University Hospital, Antwerp· Source
Active, not recruiting
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333· Phase 3· BeiGene· Source